Evidence map›Paper›PMID 32158441›Full record

ReviewFrontiers in microbiology2020

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases.

Dapeng Zhang, Sha Li, Ning Wang, Hor-Yue Tan, Zhimin Zhang, Yibin Feng

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 255 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
255citing papers in PubMed, 6 pooled it
23.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

255 citing papers in PubMed, 6 syntheses or guidelines pooled it, 426 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Frailty in COPD: Clinical Impact, Diagnosis, Biomarkers, and Management Strategies.International journal of chronic obstructive pulmonary disease · 2025
    Pooled it
  4. The Human Respiratory Microbiome: Current Understandings and Future Directions.American journal of respiratory cell and molecular biology · 2023
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. The impact for causal associations between common diseases and inflammatory bowel disease: a disease-wide bidirectional Mendelian randomization study.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. β-oxidation-mediated differentiation of effector CD4Journal of neuroinflammation · 2026
    Article
  19. Review
  20. Impact of nutrition on long COVID.Sports medicine and health science · 2026
    Review

195 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Dapeng ZhangFirst Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Sha LiSchool of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Ning WangSchool of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Hor-Yue TanSchool of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Zhimin ZhangFirst Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yibin FengSchool of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
University of Hong Kong · HKFirst Affiliated Hospital of Guangzhou Medical University · CNGuangzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging findings indicate there is a vital cross-talk between gut microbiota and the lungs, which is known as gut-lung axis. The gut disturbances in lung diseases including allergy, asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung cancer were observed by extensive studies. Investigating how gut microbiota impact other distant organs is of great interest in recent years. Although it has not been fully understood whether the disturbance is the cause or effect of lung diseases, alterations in the gut microbial species and metabolites have been linked to changes in immune responses and inflammation as well as the disease development in the lungs. In this article, we systemically review the role and mechanisms underlying the changes in the constituent of gut microbiota and metabolites in lung diseases. In particular, the roles of gut-lung axis in mediating immune responses and reshaping inflammation are highlighted. Furthermore, we discuss the potential of strategies to manipulate the gut microbiota and metabolites as the therapeutic approach for lung diseases.

Indexed as

allergyasthmachronic obstructive pulmonary diseasecystic fibrosisgut–lung axisgut microbiotalung cancerlung diseases

Identifiers

PMID32158441
PMCPMC7052046
OpenAlexW3007329745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.